Adults with COPD who used inhaled corticosteroids for more than 24 months faced higher risks for diabetes, osteoporosis, ...

"Given the added climate impact of metered-dose inhalers, health systems seeking to decrease use of these products may ...

Inhaled corticosteroids (ICS), short- and long-acting β 2-agonists (SABA and LABA), long-acting muscarinic antagonists (LAMA) and fixed ... Although these products might confer significant ...

One option is to start with an inhaled corticosteroid only before using a LABA-combination medication like Symbicort. Keep in mind that it is not safe to take an LABA without an inhaled ...

Combinations of LABA + LAMA + ICS in separate inhalers are used in patients with asthma and COPD to improve and control symptoms and to reduce exacerbations. The 4-year UPLIFT study provides the ...

are among the first data to show that a combination of a long-acting muscarinic antagonist (LAMA) and long-acting beta agonist (LABA) is more effective than a LABA combined with an inhaled ...

The FDA has requested five large clinical trials to evaluate fixed-dose ICS–LABA products with the primary outcome of life-threatening asthma exacerbation or death. The results will not be ...

a triple-therapy inhaler containing an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta-agonist (LABA), was found to offer comparable or incremental ...